Cuba vs Uzbekistan: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Cuba
99.0%
in 2025
Uzbekistan
99.0%
in 2025
Cuba rank
1st
Uzbekistan rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Cuba
- Uzbekistan
How they compare
Cuba currently reports 99.0% against 99.0% in Uzbekistan, a difference of 0.0%.
Across all 18 years both countries report, Uzbekistan has been ahead every year.
Cuba ranks 1st and Uzbekistan ranks 1st of 194 countries.
Uzbekistan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cuba | Uzbekistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 0.0% | 29.4% | 29.4% | Uzbekistan |
| 2020s | 16.5% | 97.0% | 80.5% | Uzbekistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Cuba or Uzbekistan?
- Cuba, at 99.0% against 99.0% in Uzbekistan as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Cuba and Uzbekistan?
- 0.0%, with Cuba ahead.
- How many years of comparable data are there for Cuba and Uzbekistan?
- 18 years are reported by both, from 2008 to 2025.
- How do Cuba and Uzbekistan rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Cuba ranks 1st and Uzbekistan ranks 1st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.